SomaLogic, Inc. provided revenue guidance for the year 2022. Based on ongoing strength in its business, the company is maintaining revenue guidance for the full year 2022 at a range of $105 million to $110 million, which represents 29% to 35% growth over the company's 2021 revenue.
Standard BioTools Inc.
Equities
SLGC
US83444K1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |